Table 5.
The accuracy (C-statistic, 95% confidence interval) of the three different approaches in predicting risk of progression to late AMD on the combined AREDS/AREDS2 test sets (601 participants), with the inclusion of accompanying genotype information.
| (a) Models | 1 | 2 | 3 | 4 | 5 | All years |
|---|---|---|---|---|---|---|
| Late AMD | ||||||
| Deep features/survival | 88.8 (88.0,89.7) | 85.4 (84.4,86.4) | 86.1 (85.2,86.9) | 86.9 (86.1,87.6) | 86.6 (85.8,87.4) | 86.8 (86.1,87.6) |
| DL grading/survival | 89.4 (88.2,90.6) | 83.8 (82.4,85.1) | 84.0 (83.0,85.1) | 85.0 (84.2,85.8) | 84.9 (84.2,85.6) | 85.5 (84.9,86.2) |
| Retinal specialists/calculator | – | 78.7 (78.3,79.1) | 82.4 (82.1,82.7) | 83.6 (83.3,83.8) | 83.1 (82.8,83.3) | – |
| Geographic atrophy | ||||||
| Deep features/survival | 89.5 (88.4,90.5) | 90.7 (89.9,91.5) | 88.6 (87.3,89.8) | 89.0 (88.0,89.9) | 89.5 (88.7,90.3) | 89.4 (88.7,90.2) |
| DL grading/survival | 87.0 (86.0,88.0) | 86.5 (85.6,87.5) | 85.9 (85.0,86.8) | 87.0 (86.3,87.7) | 87.6 (87.0,88.2) | 87.5 (87.0,88.0) |
| Retinal specialists/calculator | – | 77.6 (77.1,78.1) | 81.8 (81.5,82.2) | 83.0 (82.7,83.3) | 83.2 (83.0,83.5) | – |
| Neovascular AMD | ||||||
| Deep features/survival | 85.8 (84.6,87.0) | 79.1 (77.0,81.2) | 81.9 (80.6,83.3) | 82.4 (81.2,83.6) | 81.7 (80.7,82.7) | 82.6 (81.7,83.5) |
| DL grading/survival | 87.3 (86.3,88.3) | 77.3 (75.1,79.5) | 77.3 (75.6,79.0) | 78.7 (77.1,80.2) | 78.8 (77.4,80.1) | 80.0 (78.8,81.3) |
| Retinal specialists/calculator | – | 77.3 (76.6,77.9) | 82.0 (81.5,82.4) | 82.4 (82.1,82.8) | 80.9 (80.6,81.3) | – |
| (b) Models | 1 | 2 | 3 | 4 | 5 | All years |
|---|---|---|---|---|---|---|
| Late AMD | ||||||
| Deep features/survival | 87.9 (87.6,88.2) | 84.8 (84.4,85.2) | 85.9 (85.6,86.2) | 86.2 (86.0,86.4) | 86.0 (85.8,86.2) | 86.4 (86.2,86.6) |
| DL grading/survival | 84.2 (83.8,84.6) | 84.3 (84.0,84.6) | 84.9 (84.7,85.2) | 84.9 (84.7,85.1) | 85.4 (85.2,85.6) | 84.2 (83.8,84.6) |
| Geographic atrophy | ||||||
| Deep features/survival | 89.9 (89.6,90.1) | 90.1 (89.8,90.4) | 88.5 (88.2,88.8) | 88.5 (88.2,88.7) | 89.0 (88.8,89.2) | 88.7 (88.5,88.9) |
| DL grading/survival | 87.0 (86.6,87.3) | 86.2 (85.9,86.5) | 86.7 (86.5,87.0) | 87.1 (86.9,87.3) | 87.0 (86.8,87.2) | 87.0 (86.6,87.3) |
| Neovascular AMD | ||||||
| Deep features/survival | 83.7 (83.2,84.2) | 77.6 (77.0,78.3) | 81.5 (81.0,81.9) | 81.9 (81.6,82.3) | 81.3 (80.9,81.6) | 82.3 (82.1,82.6) |
| DL grading/survival | 77.6 (77.0,78.3) | 78.7 (78.2,79.2) | 79.9 (79.5,80.3) | 79.9 (79.5,80.2) | 81.0 (80.7,81.4) | 77.6 (77.0,78.3) |
(a) Use of CFH rs1061170 and ARMS2 rs10490924 status only. (b) Use of CFH/ARMS2 and the 52 SNP-based AMD Genetic Risk Score. The AMD online calculator is able to receive only CFH rs1061170 and ARMS2 rs10490924 status, not the 52 SNP-based AMD Genetic Risk Score.